Fjarde AP Fonden Fourth Swedish National Pension Fund Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,702 shares of the biopharmaceutical company’s stock after acquiring an additional 11,050 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Regeneron Pharmaceuticals were worth $23,722,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Insigneo Advisory Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares during the period. Guardian Wealth Advisors LLC NC boosted its position in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 14 shares during the period. TD Private Client Wealth LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 15 shares during the period. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 15 shares in the last quarter. Finally, Rexford Capital Inc. grew its holdings in Regeneron Pharmaceuticals by 5.5% in the 4th quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several analyst reports. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Finally, Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $900.00 to $700.00 in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $792.65.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $654.27 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market capitalization of $69.17 billion, a PE ratio of 15.94, a P/E/G ratio of 1.44 and a beta of 0.24. The stock’s fifty day moving average is $652.48 and its 200-day moving average is $725.50. Regeneron Pharmaceuticals, Inc. has a one year low of $532.60 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted $8.22 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.